RAM
KRYS icon

Resona Asset Management’s Krystal Biotech KRYS Stock Holding History

Resona Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Buy
3,387
+193
+6% +$57.7K 0.01% 621
2026
Q1 		$825K Buy
3,194
+137
+4% +$36.5K ﹤0.01% 652
2025
Q4 		$754K Hold
3,057
– – ﹤0.01% 656
2025
Q3 		$540K Buy
3,057
+140
+5% +$21K ﹤0.01% 690
2025
Q2 		$401K Buy
+2,917
New +$428K ﹤0.01% 714

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Resona Asset Management's KRYS Position: Q2 2026 in Review

Resona Asset Management increased its Krystal Biotech (KRYS) stake by 6% in Q2 2026, buying an estimated $57.7K and bringing the position to 3,387 shares worth $1.26M. The position accounts for 0.01% of the portfolio, ranked #621.

Resona Asset Management first reported a position in KRYS in Q2 2025 and has held it in 5 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Resona Asset Management held 3,387 shares of Krystal Biotech worth $1.26M as of Q2 2026.
  • Resona Asset Management bought 193 Krystal Biotech shares in Q2 2026, an estimated $57.7K.
  • Krystal Biotech made up 0.01% of Resona Asset Management's portfolio in Q2 2026, its #621 holding.
  • Resona Asset Management first reported a position in Krystal Biotech in Q2 2025 and has held it in 5 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Resona Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.